Clearpoint Neuro Stock Return On Asset
| CLPT Stock | USD 13.67 0.29 2.17% |
Clearpoint Neuro fundamentals help investors to digest information that contributes to Clearpoint Neuro's financial success or failures. It also enables traders to predict the movement of Clearpoint Stock. The fundamental analysis module provides a way to measure Clearpoint Neuro's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearpoint Neuro stock.
Clearpoint |
Clearpoint Neuro Company Return On Asset Analysis
Clearpoint Neuro's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Clearpoint Neuro Return On Asset | -0.3 |
Most of Clearpoint Neuro's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clearpoint Neuro is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Clearpoint Neuro has a Return On Asset of -0.3016. This is 96.55% lower than that of the Health Care Equipment & Supplies sector and 98.33% lower than that of the Health Care industry. The return on asset for all United States stocks is 115.43% higher than that of the company.
Clearpoint Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearpoint Neuro's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearpoint Neuro could also be used in its relative valuation, which is a method of valuing Clearpoint Neuro by comparing valuation metrics of similar companies.Clearpoint Neuro is currently under evaluation in return on asset category among its peers.
Clearpoint Fundamentals
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.72) % | ||||
| Current Valuation | 353.18 M | ||||
| Shares Outstanding | 27.63 M | ||||
| Shares Owned By Insiders | 8.00 % | ||||
| Shares Owned By Institutions | 33.26 % | ||||
| Number Of Shares Shorted | 635.68 K | ||||
| Price To Earning | (3.36) X | ||||
| Price To Book | 14.56 X | ||||
| Price To Sales | 11.78 X | ||||
| Revenue | 31.39 M | ||||
| Gross Profit | 19.12 M | ||||
| EBITDA | (19.75 M) | ||||
| Net Income | (18.91 M) | ||||
| Cash And Equivalents | 45.14 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 3.57 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 10.33 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (8.95 M) | ||||
| Short Ratio | 3.21 X | ||||
| Earnings Per Share | (0.71) X | ||||
| Price To Earnings To Growth | (0.46) X | ||||
| Target Price | 23.0 | ||||
| Number Of Employees | 115 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 369.72 M | ||||
| Total Asset | 39.19 M | ||||
| Retained Earnings | (191.37 M) | ||||
| Working Capital | 23.01 M | ||||
| Current Asset | 8.1 M | ||||
| Current Liabilities | 1.85 M | ||||
| Net Asset | 39.19 M |
About Clearpoint Neuro Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearpoint Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearpoint Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearpoint Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.